AATec Medical报告称，公司在释放AAT治疗潜力的第一年取得了重大进展-动脉网

AATec Medical reports significant progress in company’s first year towards unlocking the therapeutic potential of AAT

D-Pharm 等信源发布 2024-07-25 13:16



可切换为仅中文







AATec Medical GmbH (AATec), a biotech company developing a multi-product platform technology based on recombinant alpha-1 antitrypsin (AAT), today provided a company update, reporting on a year of major advancements in unlocking the therapeutic potential of AAT for the treatment of inflammatory respiratory diseases.

AATec Medical GmbH（AATec）是一家开发基于重组α-1抗胰蛋白酶（AAT）的多产品平台技术的生物技术公司，今天提供了一份公司最新信息，报告了一年来在释放AAT治疗炎症性呼吸道疾病潜力方面取得的重大进展。

AAT is a human serine protease inhibitor (SERPIN) that protects airway tissue from protease-induced damage. .

AAT是一种人类丝氨酸蛋白酶抑制剂（SERPIN），可保护气道组织免受蛋白酶诱导的损伤。

Dr. Rüdiger Jankowsky, co-founder and CEO of AATec, said: “We are really proud of our accomplishments in just one year. Our technological and scientific advancements, alongside strong partnerships, have established a solid groundwork for our future success. Importantly, we have advanced our lead candidate ATL-105 to treat non-cystic fibrosis bronchiectasis towards the start of clinical development, which is expected in 2025.” .

AATec联合创始人兼首席执行官Rüdiger Jankowsky博士说：“我们真的为我们在短短一年内取得的成就感到骄傲。我们的技术和科学进步，以及强大的合作伙伴关系，为我们未来的成功奠定了坚实的基础。重要的是，我们已经将我们的主要候选人ATL-105推进到治疗非囊性纤维化支气管扩张的临床开发阶段，预计将于2025年开始。”。

Dr. Karsten Ottenberg, co-founder of AATec and chairman of the board, added: “In a lean virtual setting, AATec’s highly skilled team together with strong partners and a prominent scientific network has significantly advanced the development of a drug platform in such a short time. This innovation is urgently needed to address the ever-growing global threat of respiratory diseases, especially in aging populations.

AATec联合创始人兼董事会主席Karsten Ottenberg博士补充说：“在一个精益的虚拟环境中，AATec的高技能团队以及强大的合作伙伴和杰出的科学网络在如此短的时间内极大地推动了药物平台的开发。迫切需要这项创新来应对日益增长的全球呼吸道疾病威胁，特别是在老龄化人群中。

I am proud of the team for having developed a strong rationale for our first clinical trial in non-cystic fibrosis bronchiectasis, an indication without causative treatment options and millions of patients affected worldwide. We see significant interest in this indication from clinicians and the pharmaceutical industry which confirms our strategy.” .

我为团队为我们在非囊性纤维化支气管扩张症中的首次临床试验奠定了坚实的理论基础而感到骄傲，这是一种没有病因治疗选择的适应症，全世界有数百万患者受到影响。我们看到临床医生和制药行业对这种适应症非常感兴趣，这证实了我们的策略。”。

Milestones in development of lead candidate ATL-105

主要候选人ATL-105发展的里程碑

Over the past year, AATec has successfully established a manufacturing process for a new recombinant version of AAT and developed an inhaler device using cutting-edge protein nebulization technology in cooperation with its strategic partner Beurer, a global manufacturer of healthcare product. This work is the foundation for the continued development of the company’s lead candidate ATL-105 to treat inflammatory lung diseases.AATec has achieved significant milestones in research and development, demonstrating the preclinical proof-of-principle for ATL-105 in disease models of non-cystic fibrosis bronchiectasis as well as other inflammatory respiratory diseases.

在过去的一年中，AATec成功建立了AAT新重组版本的制造工艺，并与全球医疗保健产品制造商战略合作伙伴Beurer合作，开发了一种使用尖端蛋白质雾化技术的吸入器装置。这项工作是该公司主要候选ATL-105治疗炎症性肺病的持续发展的基础。AATec在研究和开发方面取得了重大里程碑，证明了ATL-105在非囊性纤维化支气管扩张症以及其他炎症性呼吸道疾病疾病模型中的临床前原理证明。

ATL-105 has shown broad therapeutic effects: .

ATL-105已显示出广泛的治疗效果：。

Protease inhibition: Broadband activity against pro-inflammatory and tissue-damaging neutrophil serine proteases

蛋白酶抑制：对促炎和组织损伤中性粒细胞丝氨酸蛋白酶的宽带活性

Immunomodulation: Reduction of pro-inflammatory cytokines and upregulation of anti-inflammatory cytokines

免疫调节：促炎细胞因子的减少和抗炎细胞因子的上调

Broad-spectrum anti-infective activity: Wide range of effects against viral infections and inhibition of bacterial virulence factors

广谱抗感染活性：对病毒感染的广泛作用和对细菌毒力因子的抑制

Milestones in Corporate DevelopmentIn February 2024, AATec entered a collaboration with the German Federal Agency for Disruptive Innovations (SPRIN-D), which has been instrumental in validating and accelerating the research and development of ATL-105.

公司发展的里程碑2024年2月，AATec与德国联邦破坏性创新机构（SPRIN-D）合作，这有助于验证和加速ATL-105的研究和开发。

The company has also established an esteemed scientific advisory board, consisting of the scientific experts Prof. Dr. Claus Franz Vogelmeier, Prof. Dr. Ulrike Protzer, Prof. Dr. Jan Münch, and Dr. Gerhard Scheuch. With their collective expertise in respiratory diseases, airway infections, and aerosolized medicines they have significantly helped guide the development of ATL-105 from a scientific and clinical perspective.Since its foundation the company’s patent portfolio has been significantly expanded, with several patents filed for new substance matter and medical applications.

该公司还成立了一个受人尊敬的科学顾问委员会，由科学专家克劳斯·弗兰兹·沃格梅尔（Claus Franz Vogelmeier）教授、乌尔里克·普罗策（Ulrike Protzer）教授、扬·穆奇（Jan Münch）教授和格哈德·谢赫（Gerhard Scheuch）博士组成。凭借他们在呼吸系统疾病，气道感染和雾化药物方面的集体专业知识，他们从科学和临床角度极大地帮助指导了ATL-105的开发。自成立以来，该公司的专利组合已大大扩大，已申请了多项新物质和医学应用专利。

Outlook

展望

AATec plans to close its Series A financing round by fourth quarter 2024. The funds to be raised will be used to prepare and conduct a Phase 1b clinical proof-of concept trial for ATL-105 in non-cystic fibrosis bronchiectasis.

AATec计划在2024年第四季度结束其A轮融资。筹集的资金将用于准备和进行ATL-105在非囊性纤维化支气管扩张症中的1b期临床概念验证试验。

https://www.bionity.com/en/news/1184033/aatec-medical-reports-significant-progress-in-companys-first-year-towards-unlocking-the-therapeutic-potential-of-aat.html

High-tech vest monitors lung function

高科技背心监测肺功能

Machine learning algorithms aid with diagnosis

机器学习算法有助于诊断

Read news

阅读新闻